OPK Opko Health Inc.

3.54
+0.11  (+3%)
Previous Close 3.43
Open 3.5
52 Week Low 1.1171
52 Week High 4.04
Market Cap $2,371,192,975
Shares 669,828,524
Float 400,340,767
Enterprise Value $2,578,673,837
Volume 16,505,548
Av. Daily Volume 13,952,496
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Somatrogon (hGH-CTP)
Children - growth hormone deficiency
Phase 3
Phase 3
Phase 3 data met primary endpoint.
RAYALDEE
Mild-to-moderate COVID-19
Phase 2
Phase 2
Phase 2 trial to be initiated.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2b
Phase 2b
Phase 2b trial suspension announced January 31, 2019.
OPK88003
Obesity and diabetes
Phase 2b
Phase 2b
Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV
Approved
Approved
Approved September 2, 2015.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Approved
Approved
Announced June 21 2016 FDA Approval
hGH-CTP
Adults - growth hormone deficiency
Phase 3
Phase 3
Phase 3 data released December 30, 2016 - primary endpoint not met.

Latest News

  1. ELMWOOD PARK, N.J., July 1, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the results of COVID-19 molecular PCR and antibody tests for nursing home and live-in facility employees.

    On May 10, New York State mandated that all personnel at nursing home and adult care facilities were to be tested for active COVID-19 infection using PCR-based molecular testing, twice per week. The personnel tested included all employees pursuant to a plan developed by the facility and filed with the Department of Health. At the start of the program, many nursing homes asked that employees be tested for antibodies at the same time. The majority of the nearly 3,500 antibody tests were performed within the…

    ELMWOOD PARK, N.J., July 1, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the results of COVID-19 molecular PCR and antibody tests for nursing home and live-in facility employees.

    On May 10, New York State mandated that all personnel at nursing home and adult care facilities were to be tested for active COVID-19 infection using PCR-based molecular testing, twice per week. The personnel tested included all employees pursuant to a plan developed by the facility and filed with the Department of Health. At the start of the program, many nursing homes asked that employees be tested for antibodies at the same time. The majority of the nearly 3,500 antibody tests were performed within the first two weeks of May. With 29% of employees testing positive for antibodies, an extrapolated estimate for the approximately 140,000 total nursing home staff in New York State suggests as many as 41,760 nursing home staff members in New York State could have had COVID-19 prior to early May.

    Test result summary:

    Overall 29.0% of nursing home employees tested positive for antibodies

    REGION

    TEST RESULTS

    POSITIVE

    % POSITIVE

    NYC

    376

    207

    55.1%

    WESTCHESTER/ROCKLAND

    450

    167

    37.1%

    LONG ISLAND

    1068

    378

    35.4%

    UPSTATE

    1594

    258

    16.2%

    STATEWIDE

    3488

    1010

    29.0%

    Overall 2.9% of employees tested positive for active infection (positive PCR)

    REGION

    TEST RESULTS

    POSITIVE

    % POSITIVE

    NYC

    73439

    3384

    4.60%

    WESTCHESTER/ROCKLAND

    29210

    901

    3.10%

    LONG ISLAND

    53371

    638

    1.20%

    UPSTATE

    65759

    1444

    2.20%

    STATEWIDE

    221779

    6367

    2.9%

    "Of the 3,500 nursing home staff that we tested, 29% were positive for antibodies. The very high positivity rate of antibodies in this employee group by early May would suggest that a significant number of nursing home employees had active COVID-19 disease early on in the outbreak. Although overall positivity rate for active infection is now low, over 6,000 employees were identified with active virus when we tested in May and June. By identifying these individuals, the mandatory testing program most likely prevented the further spread of the virus to thousands of vulnerable nursing home residents. Although it is impossible to calculate, many deaths had to have been prevented," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "Throughout this unrelenting health crisis, BioReference has made it a priority to provide testing to those at an increased risk of COVID-19 infection, and we are proud of our efforts to help combat the spread of this virus."

    For more information, visit https://www.bioreference.com/coronavirus.  

    About BioReference Laboratories, Inc.

    BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups.  BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and an antibody test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists.  With a leading position in the areas of genetics, women's health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.

    About OPKO Health, Inc.

    OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding BioReference's antibody screening test, the availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of employees and customers, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

    Cision View original content:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-reports-results-of-covid-19-testing-for-almost-one-quarter-of-a-million-nursing-home-and-live-in-facility-employees-301086786.html

    SOURCE BioReference Laboratories, Inc.

    View Full Article Hide Full Article
  2. MIAMI, June 09, 2020 (GLOBE NEWSWIRE) -- Following last October's announcement of successful results of the global Phase 3 study of once-weekly somatrogon, an investigational agent for the treatment of pediatric growth hormone deficiency (pGHD), OPKO Health Inc. (NASDAQ:OPK) announced today that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® (somatropin) for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD. The findings were consistent with the results previously reported in the Phase 3 global study…

    MIAMI, June 09, 2020 (GLOBE NEWSWIRE) -- Following last October's announcement of successful results of the global Phase 3 study of once-weekly somatrogon, an investigational agent for the treatment of pediatric growth hormone deficiency (pGHD), OPKO Health Inc. (NASDAQ:OPK) announced today that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® (somatropin) for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD. The findings were consistent with the results previously reported in the Phase 3 global study.

    Using the Full Analysis Set, the least squared means for the annual height velocity was higher in the somatrogon group (9.65 cm/year) than in the GENOTROPIN group (7.87 cm/year). The point estimate of the treatment difference was 1.79 cm/year with the two-sided 95% confidence interval of (0.97, 2.60). Similarly, greater change in height standard deviation score from baseline at 12 months was observed for the somatrogon group (0.94) compared to the GENOTROPIN group (0.52), indicating that both somatrogon and GENOTROPIN were associated with catch-up growth in treated patients.

    Most adverse events were mild to moderate in severity with no notable differences between the treatment groups, and weekly somatrogon administration was generally well-tolerated. A total of six serious adverse events were reported in four patients (two in the somatrogon arm and two in the GENOTROPIN arm). One patient in the GENOTROPIN group discontinued treatment in the study due to adverse events.

    "We are pleased to announce positive top-line results from the Japanese Phase 3 clinical study of somatrogon. We have reached an additional clinical development milestone of somatrogon with the demonstration of comparable efficacy and safety of somatrogon administered once-weekly to daily administration of GENOTROPIN in pediatric patients with growth hormone deficiency," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Positive results in both the Japanese and pivotal global Phase 3 pediatric trials are promising for children with pGHD. Treatment with once-weekly somatrogon represents a significant advance, which has the potential to enhance patient adherence and quality of life."

    "The data from the Japan Phase 3 trial are very encouraging and point to the potential of bringing a once-weekly treatment option to children with pGHD. We are committed to furthering treatment advances for people living with rare growth hormone disorders and this is an exciting advance that may help ease the daily disease burden for children and their caregivers," said Brenda Cooperstone, M.D., Chief Development Officer, Rare Disease, Pfizer Global Product Development.

    In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD. Under the agreement, OPKO is responsible for conducting the clinical program and Pfizer is responsible for registering and commercializing the product. The companies will evaluate the potential for additional pediatric and adult indications, as appropriate.

    About the Study

    The Phase 3 study of somatrogon in 44 treatment-naïve Japanese pre-pubertal children with pGHD was a 12-month, open-label, randomized, active-controlled, parallel-group study of the efficacy and safety of weekly somatrogon compared to recombinant human growth hormone (r-hGH), GENOTROPIN® (somatropin) for injection treatment administered once-daily. Eligible patients were randomized in a 1:1 ratio to receive either once-weekly somatrogon or GENOTROPIN administered once-daily (reference therapy, 0.025 mg/kg/day which is equivalent to 0.175 mg/kg/week). To obtain pharmacokinetic information of three different weekly doses in Japanese pGHD patients, somatrogon treated patients received 0.25 mg/kg/week for 2 weeks, followed by 0.48 mg/kg/week for 2 weeks followed by 0.66 mg/kg/week for the remaining 46 weeks.  Somatrogon was administered subcutaneously using a single patient use, multi-dose, disposable, pre-filled pen, the same pen used in the global study, while GENOTROPIN was administered using approved commercial products in Japan.

    Patients who completed the 12-month Main Study Period and met the inclusion criteria were given the opportunity to continue in a long-term open label extension period with once-weekly somatrogon until marketing approval. All patients in the GENOTROPIN group have been switched to weekly somatrogon treatment.

    About Somatrogon

    Somatrogon is a new molecular entity that contains the natural sequence of human growth hormone and one copy of the C-terminal peptide (CTP) from the beta chain of human chorionic hCG at the N-terminus and two copies at the C-terminus. The CTPs extend the half-life of the molecule. Somatrogon received Orphan Drug designation in the U.S. and the EU for the treatment of children and adults with growth hormone deficiency.

    About Growth Hormone Deficiency

    Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland and affects one in approximately 4,000 to 10,000 people. In children, this disease can be caused by genetic mutations or acquired after birth. Because the patient's pituitary gland secretes inadequate levels of somatropin, the hormone that causes growth, his or her height may be affected and puberty may be delayed. Without treatment, he or she will have persistent growth attenuation, a very short height in adulthood and may experience other health problems.

    About GENOTROPIN®

    GENOTROPIN is a recombinant growth hormone as a replacement treatment option, approved in the United States for children who do not make enough growth hormone on their own, have the genetic condition called Prader-Willi syndrome (PWS), were born smaller than most other babies, have the genetic condition called Turner syndrome (TS) or have idiopathic short stature (ISS). GENOTROPIN is also approved in the United States to treat adults with growth hormone deficiency. GENOTROPIN is taken by injection just below the skin and is available in a wide range of devices to fit a range of individual dosing needs.  GENOTROPIN is distributed by Pharmacia and Upjohn Co., a division of Pfizer, Inc.

    About OPKO Health, Inc.

    OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This release contains forward-looking information about a product candidate, somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (or GHD), including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for somatrogon; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether somatrogon will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of somatrogon; and competitive developments.

    A further description of risks and uncertainties can be found in OPKO's Annual Reports on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors", "Forward-Looking Information and Factors That May Affect Future Results", "Cautionary Statement Regarding Forward-Looking Statements", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.OPKO.com.

    Contacts:

    LHA Investor Relations

    Yvonne Briggs, 310-691-7100



    or

    Bruce Voss, 310-691-7100

    Primary Logo

    View Full Article Hide Full Article
  3. MIAMI, June 01, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that the U.S. Food and Drug Administration (FDA) has authorized OPKO to undertake a Phase 2 trial with RAYALDEE® as a treatment for patients with mild-to-moderate COVID-19.  The trial, entitled "A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue)," is estimated to enroll 166 subjects, including many with stage 3 or 4 chronic kidney disease (CKD).

    The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up.  The objective is to raise and maintain serum total 25-hydroxyvitamin…

    MIAMI, June 01, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that the U.S. Food and Drug Administration (FDA) has authorized OPKO to undertake a Phase 2 trial with RAYALDEE® as a treatment for patients with mild-to-moderate COVID-19.  The trial, entitled "A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue)," is estimated to enroll 166 subjects, including many with stage 3 or 4 chronic kidney disease (CKD).

    The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up.  The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.

    "Raising serum 25D enables macrophages, a type of white blood cell of the immune system, to secrete potent antiviral proteins that can destroy SARS-CoV-2, the virus that causes COVID-19," explained Charles W. Bishop, PhD, CEO of OPKO's Renal Division.  "It also can suppress the cytokine storm triggered by viral infection."

    COVID-19 disproportionately afflicts patients with obesity, older age, darker skin or CKD, all of which are risk factors for reduced serum 25D. Raising 25D sufficiently with supplements is difficult.

    About RAYALDEE®

    RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3.  The product is the first and only medicine approved by the U.S. FDA for raising serum total 25D and lowering blood levels of intact parathyroid hormone (iPTH). RAYALDEE, approved to treat secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 CKD and vitamin D insufficiency, was launched in November 2016. 

    About OPKO Health, Inc.

    OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "could," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including product development efforts and the expected benefits of RAYALDEE, whether and when we will initiate and complete the clinical studies contemplated for RAYALDEE and whether final study data will be positive, our ability to develop and commercialize RAYALDEE for COVID-19 patients, whether RAYALDEE is capable of treating patients with COVID-19, impacting the SARS-CoV-2 virus or cytokine storm, or have any impact on the severity of the disease or that it will effectively raise and maintain serum total 25D consistently at or above 50ng/mL, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects.  Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, the success of our relationship with our commercial partners for RAYALDEE, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, and that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

    CONTACTS:
    Investors
    LHA Investor Relations
    Yvonne Briggs, 310-691-7100

    or
    Bruce Voss, 310-691-7100

    Primary Logo

    View Full Article Hide Full Article
  4. NEW YORK, May 18, 2020 /PRNewswire/ -- MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaboration with BioReference, MagnaCare will offer on-site antibody blood testing to Labor members, delivering valuable information as the city, employers and individuals plan return-to-work strategies.

    "As New York's coronavirus outbreak has continued to unfold, our Labor partners have been eager for information and guidance on COVID-19 antibody testing — particularly since skilled trade groups will be among the first to return-to-work and begin re-energizing the local economy…

    NEW YORK, May 18, 2020 /PRNewswire/ -- MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaboration with BioReference, MagnaCare will offer on-site antibody blood testing to Labor members, delivering valuable information as the city, employers and individuals plan return-to-work strategies.

    "As New York's coronavirus outbreak has continued to unfold, our Labor partners have been eager for information and guidance on COVID-19 antibody testing — particularly since skilled trade groups will be among the first to return-to-work and begin re-energizing the local economy," said MagnaCare President Michelle Zettergren. "Antibody testing can support decision making about back-to-work procedures and safety measures for protecting workers and the public. We're proud to bring this service to our clients so they have more knowledge, and hopefully some peace of mind, in this challenging environment."

    BioReference Laboratories, which recently worked with New York State and New York City to provide COVID-19 antibody testing, offers a blood test that measures SARS-CoV-2 specific antibody levels to help determine an individual's immune response after COVID-19 infection. Although the presence of antibodies are typically associated with immunity, the scientific community is still working to understand what level of antibodies might be needed for protection from reinfection with COVID-19, and how long that protection might last.

    The collaboration will begin with on-site testing for the District Council 9 of the International Union of Painters and Allied Trades (IUPAT) on May 18-20. The on-site testing is available to DC 9 members, who must go online to pre-register and schedule their test. The cost will be fully covered by the union, and results will be emailed directly to members within 72 hours.

    "Our goal is to get our members back to work with comfort and confidence," said Joseph Azzopardi, Business Manager and Secretary Treasurer of DC 9. "We're grateful to MagnaCare for providing a convenient testing option so we can all decide how best to move forward in the days and weeks ahead."

    MagnaCare is also working with some of its other New York-based Labor partners to establish additional on-site testing locations this month.

    About MagnaCare
    For more than 25 years, MagnaCare has been building healthy communities together with Taft-Hartley funds, TPAs, carriers, and workers' compensation and no-fault payors in the New York, New Jersey, and Connecticut tristate area. Its broad and wholly owned network, full health plan management services, comprehensive in-house medical management, and leading outcomes-based casualty solutions offer the ultimate flexibility and customization that help customers control health care costs, improve health, and achieve exceptional value. MagnaCare is a division of Brighton Health Plan Solutions, LLC

    About BioReference Laboratories, Inc.
    BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups.  The company is in network with the five largest health plans in the United States, operates a network of 10 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists.  With a leading position in the areas of genetics, women's health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine.  For more information, visit www.bioreference.com.

    Media Contact for MagnaCare:
    Erin George
     
    615-946-9914

    Media Contact for BioReference Laboratories:
    Hillary Titus

    201-406-9968

    Cision View original content:http://www.prnewswire.com/news-releases/magnacare-and-bioreference-laboratories-bring-covid-19-antibody-testing-to-new-york-labor-groups-301060258.html

    SOURCE Brighton Health Plan Solutions

    View Full Article Hide Full Article
  5. ELMWOOD PARK, N.J., May 13, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today launched the BioReference Employer Solution, a COVID-19 screening program that assists employers' decisions about return-to-work policies.

    Test results play a critical role in the fight against COVID-19 by identifying who has detectable antibodies, and providing the amount of antibodies measured. Combining other clinical information and guidance from health authorities, these results can inform decisions on enhancing the safety of employees and customers. 

    To support return-to-work strategies and COVID-19 antibody screening efforts, BioReference is offering flexible specimen collection options tailored to each employer, including a plug-and-play program in a designated location for employees or at one of BioReference's large pop-up sites. The first pop-up site will open at the Livingston Mall in Livingston, New Jersey, beginning on May 15.

    Livingston Mall COVID-19 Testing Location:
    112 Eisenhower Parkway, Livingston, NJ 07039
    In the parking lot between Lord & Taylor and Macy's
    Mondays through Saturdays beginning May 15, 2020
    8AM6PM ET

    The BioReference Employer Solution provides digital registration and check-in, onsite testing and processing, and online result access. BioReference can tailor the offering of testing depending on an organization's size and preference, which can include site identification and set-up services, and phlebotomy services. 

    "For employers, COVID-19 screening for antibodies is one additional piece of information to help guide decisions about moving forward," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "Antibody testing can provide employers key information about who might have been exposed or infected, and who may potentially be immune from re-infection. It's our responsibility to add to the body of knowledge for this virus, and we believe antibody screening can be helpful to guide us toward a new normal."

    For more information, visit https://www.bioreference.com/coronavirus/employers-and-government-authorities/.    

    About BioReference Laboratories, Inc.
    BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups.  The company is in network with the five largest health plans in the United States, operates a network of 10 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists.  With a leading position in the areas of genetics, women's health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine.  For more information, visit https://www.bioreference.com.

    About OPKO Health, Inc.
    OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

    Cautionary Statement Regarding Forward-Looking Statements
    This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding BioReference's antibody screening test, the availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of employees and customers, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-launches-covid-19-employer-solution-301058864.html

    SOURCE BioReference Laboratories, Inc

    View Full Article Hide Full Article
View All Opko Health Inc. News